SS
ITCI icon

Simplicity Solutions’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Simplicity Solutions’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,639
Closed -$250K – 547
2015
Q4 		$250K Buy
+4,639
New +$234K 0.03% 563

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Simplicity Solutions's ITCI Position: Q1 2016 in Review

Simplicity Solutions sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2016, closing a stake of 4,639 shares — an estimated $250K sold.

Simplicity Solutions first reported a position in ITCI in Q4 2015 and held it in 1 quarter. The position peaked at $250K in Q4 2015. 127 funds tracked by Wall St. Rank hold ITCI as of Q1 2016.

  • Simplicity Solutions reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2016 after selling out during the quarter.
  • Simplicity Solutions sold 4,639 Intra-Cellular Therapies Inc. shares in Q1 2016, an estimated $250K.
  • Simplicity Solutions first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 1 quarter.
  • Simplicity Solutions's Intra-Cellular Therapies Inc. position peaked at $250K in Q4 2015.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2016.

Based on Simplicity Solutions's 13F filing for Q1 2016, filed 26 Apr 2016.